Durvalumab
- Generic Name
- Durvalumab
- Brand Names
- Imfinzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1428935-60-7
- Unique Ingredient Identifier
- 28X28X9OKV
- Background
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tum...
- Indication
Durvalumab is indicated for the treatment of adults with the following conditions:
- Associated Conditions
- Extensive-stage Small Cell Lung Cancer (SCLC), Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer, Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Stage III Non-small Cell Lung Cancer, Unresectable, locally advanced PD-L1 positive Lung Cancer Non-Small Cell Cancer (NSCLC)
- Associated Therapies
- First Line Chemotherapy
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2024-01-23
- Target Recruit Count
- 40
- Registration Number
- NCT05239169
- Locations
- 🇩🇪
Krankenhaus Nordwest, Frankfurt am Main, Germany
Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 62
- Registration Number
- NCT05222971
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 999
- Registration Number
- NCT05221840
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)
- Conditions
- Interventions
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 200
- Registration Number
- NCT05215106
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
🇫🇷Institut Bergonié, Bordeaux, France
🇫🇷Centre Léon Berard, Lyon, France
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
- Conditions
- Interventions
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 860
- Registration Number
- NCT05211895
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Chemo-free BRCA-targeted Neoadjuvant Strategy
- Conditions
- Interventions
Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2022-02-11
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 25
- Registration Number
- NCT05206812
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT05198830
- Locations
- 🇺🇸
Robert Wood Johnson University Hospital Somerset, Somerville, New Jersey, United States
🇺🇸Keck Medicine of USC Buena Park, Buena Park, California, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 121
- Registration Number
- NCT05170204
- Locations
- 🇮🇳
Medanta-The Medicity, Gurgaon, Haryana, India
🇹🇷Dicle University Faculty of Medicine, Diyarbakir, Turkey
🇺🇸University of South Alabama; Mitchell Cancer Institute, Mobile, Alabama, United States
Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2021-12-15
- Lead Sponsor
- Juan LI, MD
- Target Recruit Count
- 9
- Registration Number
- NCT05157542
- Locations
- 🇨🇳
Sichuan Cancer Hospital, Chengdu, Sichuan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.